Biotechnologia Acta

...

  • Increase font size
  • Default font size
  • Decrease font size
Home Archive 2020 № 2 TRANSLATION MEDICINE, BIOMEDICINE AND MEDICAL BIOTECHNOLOGY: THE TRANSITION TO PERSONALIZED MEDICINE Pereginya O. V., Lutsenko T. M.
Print PDF

ISSN 2410-7751 (Print)
ISSN 2410-776X (Online)

Biotechnologia Acta V. 13, No 2, 2020
Р. 5-11, Bibliography 19, English
Universal Decimal Classification: 573.6 + 616-092
https://doi.org/10.15407/biotech13.02.005

TRANSLATION MEDICINE, BIOMEDICINE AND MEDICAL BIOTECHNOLOGY: THE TRANSITION TO PERSONALIZED MEDICINE

Pereginya O. V., Lutsenko T. M.

National Technical University of Ukraine “Igor Sikorsky Kyiv Polytechnic” Institute”

Given that biomedical research in the field of molecular and cellular foundations of pathogenesis has been actively developing in the last two decades, there is a need for active collaboration between scientific and laboratory institutions to create new and improve existing methods of treatment to provide effective professional care for the patient. The transition to personalized therapy, which aims to create methods of treatment adapted to a specific group of patients or individual, became a big step in the field of translational medicine. An important issue is the introduction of translational medicine into modern clinical practice and its development ensuring on the basis of scientific centers and institutes.

The purpose of the article was to analyze and summarize information regarding translational medicine and its implementation in treatment and scientific and practic activity to ensure more effective therapy for patients.

The literature concerning the development of translational medicine, its application in clinical practice and methods of implementation in the scientific field was reviewed and analyzed. The information about personalized medicine was generalized.

Translational medicine contributes to the practical application of scientific advances to the development and implementation of new methods of prevention, diagnostics, treatment and rehabilitation. An important characteristic of translational medicine is its double-sided concept, which consists in the collaboration of laboratory and clinical institutions in order to regularly information exchange. The introduction of personalized medicine allows, based on the individual characteristics of the patient, to find an effective approach to treatment.

Translational medicine is a promising area of treatment, the introduction of which in clinical practice would enable to create and improve effective methods of various diseases therapy. The widespread use of personalized medicine will increase the percentage of positive treatment outcomes due to the individual approach to each patient. For the active development and spread of this type of therapy, there is a need to create more institutes of translational medicine, to hold scientific conferences on this subject, and to introduce into the curricula of universities the disciplines for the study of the basics of translational medicine.

Key words: translational research, translational medicine, cancer, personalized medicine.

© Palladin Institute of Biochemistry of National Academy of Sciences of Ukraine, 2020

  • References
    • 1. Ipatova O. M., Medvedeva N. V., Archakov A. I., Grigor’ev A. I. Translational medicine as a way from fundamental biomedical science to public health services. J. RAMS. 2012, V. 6, P. 57‒65.
      https://doi.org/10.15690/vramn.v67i6.285

      2. Rubio D. McGartland, Schoenbaum E. E., Lee L. S., Schteingart D. E., Marantz P. R., Anderson K. E., Platt L. D., Baez A., Esposito K. Defining Translational Research: Implications for Training. Acad. Med. 2010, 85 (3), 470‒475.
      https://doi.org/10.1097/ACM.0b013e3181ccd618

      3. Littman B. H, Krishna R. Translational Medicine and Drug Discovery. Cambridge University Press. 2011, 361 p.

      4. Tatonetti N. P. Translational medicine in the Age of Big Data. Briefings in Bioinformatics. 2019, 20 (2), 457–462.
      https://doi.org/10.1093/bib/bbx116

      5. Jorge Otávio Maia Barreto, Everton Nunes da Silva, Rodrigo Gurgel-Gonçalves, Suélia de Siqueira Rodrigues Fleury Rosa, Maria Sueli Soares Felipe, Leonor Maria Pacheco Santos. Translational research in public health: challenges of an evolving field. Saude Debate. 2019, 43 (2), 4‒9.
      https://doi.org/10.1590/0103-11042019s200

      6. Zerhouni E. A. Translational and clinical science-time for a new vision. N. Engl. J. Med. 2005, 353 (15), 1621‒1623.
      https://doi.org/10.1056/NEJMsb053723

      7. Marincola F. M. Translational medicine: A two-way road. J. Transl. Med. 2003, 1 (1), 32‒33.
      https://doi.org/10.1186/1479-5876-1-11

      8. Littman B. H., Di Mario L., Plebani M., Marincola F. M. What’s next in translational medicine? Clin. Sci. (Lond). 2007, 112 (4), 217‒227.
      https://doi.org/10.1042/CS20060108

      9. Abernethy A. P, Wheeler J. L. True translational research: bridging the three phases of translation through data and behavior. Transl. Behav. Med. 2011, 1 (1), 26–30.
      https://doi.org/10.1007/s13142-010-0013-z

      10. Cohrs R. J., Martin T., Ghahramani P., Bidaut L., Higgins P. J., Shahzad A. Translational Medicine definition by the European Society for Translational Medicine. New Horizons in Translational Medicine. 2015, V. 2, P. 86‒88.
      https://doi.org/10.1016/j.nhtm.2014.12.002

      11. Vogenberg F. R., Barash C. I., Pursel M. Personalized Medicine. Part 1: Evolution and Development into Theranostics. Pharmacy and Therapeutics. 2010, 35 (10), 60–67.

      12. Paltsev M. A., Belushkina N. N. Translational medicine ‒ a new stage of molecular medicine development. Mol. Med. 2012, V. 4, P. 3‒6.

      13. Hendriks B., Simons A., Reinhart M. What are clinician scientists expected to do? The undefined space for professionalizable work in translational biomedicine. Minerva. 2019, 57 (2), 219–237.
      https://doi.org/10.1007/s11024-019-09367-4

      14. Futreal P. A., Coin L., Marshall M. Down T., Hubbard T., Wooster R., Rahman N., Stratton M. R. A census of human cancer genes. Nat. Rev. Cancer. 2004, 4 (3), 177–183. https://doi.org/10.1038/nrc1299

      15. Grigorenko V. R. Modern methods of morphological diagnosis and prognosis of serous ovarian tumors. Bull. Probl. Boil. Med. 2018, 2 (144), 17–22.
      https://doi.org/10.29254/2077-4214-2018-2-144-17-22

      16. Suh K. S., Park S. W., Castro A., Patel H., Blake P., Liang M., Goy A. Ovarian cancer biomarkers for molecular biosensors and translational medicine. Expert. Rev. Mol. Diagn. 2010, 10 (8), 1069–1083. https://doi.org/10.1586/erm.10.87

      17. Darcy K. M., Birrer M. J. Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol. Oncol. 2010, 117 (3), 429–439.
      https://doi.org/10.1016/j.ygyno.2010.01.048

      18. Eschenhagen T., Force T., Ewer M. S., de Keulenaer G. W., Suter T. M., Anker S. D., Avkiran M., de Azambuja E., Balligand J.-L., Brutsaert D. L., Condorelli G., Hansen A., Heymans S., Hill J. A., Hirsch E., Hilfiker-Kleiner D., Janssens S., de Jong S., Neubauer G., Pieske B., Ponikowski P., Pirmohamed M., Rauchhaus M., Sawyer D., Sugden P. H., Wojta J., Zannad F., Shah A. M. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2011, 13 (1), 1–10. https://doi.org/10.1093/eurjhf/hfq213

      19. Chekhun V. F. From system biology of cancer to methodology of personalized treatment. Oncology. 2012, 14 (2), 84‒88.


1. Ipatova O. M., Medvedeva N. V., Archakov A. I., Grigor’ev A. I. Translational medicine as a way from fundamental biomedical science to public health services. J. RAMS. 2012, V. 6, P. 57‒65.

2. Rubio D. McGartland, Schoenbaum E. E., Lee L. S., Schteingart D. E., Marantz P. R., Anderson K. E., Platt L. D., Baez A., Esposito K. Defining Translational Research: Implications for Training. Acad. Med. 2010, 85 (3), 470‒475.

3. Littman B. H, Krishna R. Translational Medicine and Drug Discovery. Cambridge University Press. 2011, 361 p.

4. Tatonetti N. P. Translational medicine in the Age of Big Data. Briefings in Bioinformatics. 2019, 20 (2), 457–462.

5. Jorge Otávio Maia Barreto, Everton Nunes da Silva, Rodrigo Gurgel-Gonçalves, Suélia de Siqueira Rodrigues Fleury Rosa, Maria Sueli Soares Felipe, Leonor Maria Pacheco Santos. Translational research in public health: challenges of an evolving field. Saude Debate. 2019, 43 (2), 4‒9.

6. Zerhouni E. A. Translational and clinical science-time for a new vision. N. Engl. J. Med. 2005, 353 (15), 1621‒1623.

7. Marincola F. M. Translational medicine: A two-way road. J. Transl. Med. 2003, 1 (1), 32‒33.

8. Littman B. H., Di Mario L., Plebani M., Marincola F. M. What’s next in translational medicine? Clin. Sci. (Lond). 2007, 112 (4), 217‒227.

9. Abernethy A. P, Wheeler J. L. True translational research: bridging the three phases of translation through data and behavior. Transl. Behav. Med. 2011, 1 (1), 26–30.

10. Cohrs R. J., Martin T., Ghahramani P., Bidaut L., Higgins P. J., Shahzad A. Translational Medicine definition by the European Society for Translational Medicine. New Horizons in Translational Medicine. 2015, V. 2, P. 86‒88.

11. Vogenberg F. R., Barash C. I., Pursel M. Personalized Medicine. Part 1: Evolution and Development into Theranostics. Pharmacy and Therapeutics. 2010, 35 (10), 60–67.

12. Paltsev M. A., Belushkina N. N. Translational medicine ‒ a new stage of molecular medicine development. Mol. Med. 2012, V. 4, P. 3‒6.

13. Hendriks B., Simons A., Reinhart M. What are clinician scientists expected to do? The undefined space for professionalizable work in translational biomedicine. Minerva. 2019, 57 (2), 219–237.

14. Futreal P. A., Coin L., Marshall M. Down T., Hubbard T., Wooster R., Rahman N., Stratton M. R. A census of human cancer genes. Nat. Rev. Cancer. 2004, 4 (3), 177–183. https://doi.org/10.1038/nrc1299

15. Grigorenko V. R. Modern methods of morphological diagnosis and prognosis of serous ovarian tumors. Bull. Probl. Boil. Med. 2018, 2 (144), 17–22.

16. Suh K. S., Park S. W., Castro A., Patel H., Blake P., Liang M., Goy A. Ovarian cancer biomarkers for molecular biosensors and translational medicine. Expert. Rev. Mol. Diagn. 2010, 10 (8), 1069–1083. https://doi.org/10.1586/erm.10.87

17. Darcy K. M., Birrer M. J. Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol. Oncol. 2010, 117 (3), 429–439.

18. Eschenhagen T., Force T., Ewer M. S., de Keulenaer G. W., Suter T. M., Anker S. D., Avkiran M., de Azambuja E., Balligand J.-L., Brutsaert D. L., Condorelli G., Hansen A., Heymans S., Hill J. A., Hirsch E., Hilfiker-Kleiner D., Janssens S., de Jong S., Neubauer G., Pieske B., Ponikowski P., Pirmohamed M., Rauchhaus M., Sawyer D., Sugden P. H., Wojta J., Zannad F., Shah A. M. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2011, 13 (1), 1–10. https://doi.org/10.1093/eurjhf/hfq213

19. Chekhun V. F. From system biology of cancer to methodology of personalized treatment. Oncology. 2012, 14 (2), 84‒88.

 

Additional menu

Site search

Site navigation

Home Archive 2020 № 2 TRANSLATION MEDICINE, BIOMEDICINE AND MEDICAL BIOTECHNOLOGY: THE TRANSITION TO PERSONALIZED MEDICINE Pereginya O. V., Lutsenko T. M.

Invitation to cooperation

Dear colleagues, we invite you to publish your articles in our journal.
© Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, 2008.
All rights are reserved. Complete or partial reprint of the journal is possible only with the written permission of the publisher.
E-mail
for information: biotech@biochem.kiev.ua.